Radix Actinidiae Chinensis Extract for Ulcerative Colitis Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ulcerative colitis, such as aminosalicylic acids and mesalazine, are costly, have adverse reactions, and fail to effectively maintain remission and prevent recurrence, posing a significant economic burden and health risk.
Innovation Solution
Utilizing a radix actinidiae chinensis extract, either water or alcohol-based, to inhibit inflammatory factors IL-8, IL-17, and TNFα, reduce colorectal shortening and occult blood production, and decrease weight loss, thereby treating ulcerative colitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mesalazine is used for long-term treatment of ulcerative colitis, then remission can be maintained, but adverse reactions including liver damage occur and economic burden increases
Solution Approach 1:
The patent uses a natural extract from kiwifruit vine (Actinidia chinensis) as a short-term, cost-effective alternative to long-term mesalazine therapy. The extract achieves therapeutic effects without the cumulative adverse reactions associated with prolonged conventional treatment, allowing patients to maintain remission without ongoing liver monitoring and associated costs.
Solution Approach 2:
The patent changes the chemical parameter from synthetic mesalazine to a natural polyphenolic extract containing multiple active compounds. This parameter change transforms the treatment profile from one with narrow therapeutic window and cumulative toxicity to one with broader safety margin and different mechanism of action, reducing adverse reactions while maintaining efficacy.
2Reliability
If mesalazine is used for long-term treatment, then disease control is achieved, but medical resources are consumed and treatment cost increases
Solution Approach 1:
The natural extract serves as a cost-effective treatment that reduces consumption of expensive medical resources. By achieving disease control with a naturally-derived, lower-cost agent, the patent reduces the quantity of medical resources required for long-term management, including fewer monitoring tests and associated healthcare expenditures.
3Ease of operation
If conventional medicines are used for ulcerative colitis, then some symptom relief is achieved, but efficacy in preventing recurrence and promoting deep healing is insufficient
Solution Approach 1:
The patent employs a composite natural extract containing multiple polyphenolic compounds (including actinidin, actinidiin, and other phenolic acids) that work synergistically. This composite material provides both symptom relief and deep mucosal healing through multiple mechanisms of action, addressing both immediate symptoms and underlying inflammation to prevent recurrence more effectively than single-agent conventional therapies.
Data Source
AI summary
Use of radix actinidiae chinensis and an extract thereof in preparation of a medicine for treating ulcerative colitis are provided. The radix actinidiae chinensis extract is a radix actinidiae chinensis water extract or a radix actinidiae chinensis alcohol extract. The radix actinidiae chinensis extract has an obvious anti-inflammatory effect on the ulcerative colitis; and because the radix actinidiae chinensis extract has the obvious anti-inflammatory effect on the ulcerative colitis, the radix actinidiae chinensis serving as a raw material also has an obvious anti-inflammatory effect on the ulcerative colitis. Moreover, the radix actinidiae chinensis is widely distributed in China, and is widely cultivated in Shaanxi and other regions. Moreover, the radix actinidiae chinensis is a traditional Chinese medicine for clearing away heat and toxic materials, and its toxic and side effects are small.